FDA to review uniQure's Huntington's gene therapy, decision due on May 2027

What happened

UniQure said the FDA accepted its application for AMT-130, its Huntington’s disease gene therapy, and expects a decision by May 1, 2027. The FDA granted a faster review and is considering an outside-expert meeting. The application uses early- to mid-stage results compared with an external patient database.

Confirmed

Global impact / market context

FDA review keeps a potential US approval route open despite the earlier trial result that did not show slower disease progression. If approval follows, it could enable sales; however, accelerated approval relies on early evidence and may require later studies to confirm benefit, leaving commercial prospects uncertain.

Analyst inference

FDA review creates a possible route from early study evidence to approval, but the prior trial did not slow disease progression. If approval requires further studies, uniQure would need to complete them to confirm benefit, linking future research spending and patient recruitment to the treatment’s commercial prospects.

Analyst inference

What to watch

1. Watch for the FDA’s decision by May 1, 2027, and whether it convenes outside experts; either could clarify the review’s timing and the evidence regulators consider important. Confirmed
2. UniQure plans to start US patient screening by year-end for a 200-patient follow-up trial; completion and results could test whether AMT-130’s benefit is confirmed. Proposed
3. The accelerated pathway can permit approval based on early evidence, with later confirmation required; failure to confirm benefit could weaken the therapy’s commercial prospects and expected sales. Analyst inference

Evidence

• Original source link unavailable